公开(公告)号：US20230051268A1

公开(公告)日：2023-02-16

申请号：US17757672

申请日：2020-12-18

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Andrew SATLIN ,  Margaret MOLINE ,  Ishani LANDRY

IPC: A61K31/506 ,  A61K9/00

Abstract: Disclosed are methods for treating insomnia, comprising administering orally a dosage form comprising Lemborexant or a pharmaceutically acceptable salt thereof to a patient in need thereof at a single daily dose ranging from 5 mg to 10 mg of lemborexant or an equivalent dose of a pharmaceutically acceptable salt thereof, provided that the maximum dose is 5 mg once per day of lemborexant or an equivalent dose of a pharmaceutically acceptable salt thereof when the patient has moderate hepatic impairment classified in Child-Pugh class B under Child-Pugh Classification.

公开(公告)号：US20200268754A1

公开(公告)日：2020-08-27

申请号：US16819341

申请日：2020-03-16

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Margaret MOLINE ,  Gina PASTINO ,  Yurie AKIMOTO ,  Yasuhiro ZAIMA ,  Nobuya SUZUKI ,  Nobuo YOSHIDA

IPC: A61K31/506 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48

Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

公开(公告)号：US20170252342A1

公开(公告)日：2017-09-07

申请号：US15519676

申请日：2015-10-21

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Margaret MOLINE ,  Gina PASTINO ,  Yurie AKIMOTO ,  Yasuhiro ZAIMA ,  Nobuya SUZUKI ,  Nobuo YOSHIDA

IPC: A61K31/506 ,  A61K9/48 ,  A61K9/20 ,  A61K9/00

CPC classification number: A61K31/506 ,  A61K9/0053 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/48 ,  A61K9/4858 ,  A61K9/4866

Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

公开(公告)号：US20220305012A1

公开(公告)日：2022-09-29

申请号：US17597074

申请日：2020-06-25

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Margaret MOLINE ,  Lynn KRAMER ,  Shobha DHADDA

IPC: A61K31/506 ,  A61P25/20

Abstract: Methods of improving subjective sleep efficiency, reducing subjective sleep onset latency, and/or reducing subjective wake after sleep onset in subjects comprising administering to the subject 5 mg or 10 mg of lemborexant or an equivalent dose of a pharmaceutically acceptable salt thereof are disclosed herein. Also disclosed herein is lemborexant or a pharmaceutically acceptable salt thereof for use in improving subjective sleep efficiency, reducing subjective sleep onset latency, and/or reducing subjective wake after sleep onset in a subject comprising administering to the subject 5 mg or 10 mg of lemborexant or an equivalent dose of a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190201399A1

公开(公告)日：2019-07-04

申请号：US16255116

申请日：2019-01-23

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Margaret MOLINE ,  Gina PASTINO ,  Yurie AKIMOTO ,  Yasuhiro ZAIMA ,  Nobuya SUZUKI ,  Nobuo YOSHIDA

IPC: A61K31/506 ,  A61K9/48 ,  A61K9/00 ,  A61K9/20

Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.